Welcome to AiCuris: The Powerhouse for Anti-Infectives
AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.
Pritelivir Fast Track Designation
AiCuris Granted Fast Track Designation by U.S. FDA for Oral Pritelivir for Treatment of HSV Infections in Immunocompromised Adults
Fast track is a process designed to facilitate the development, expedite the review and accelerate the approval process of drugs to treat serious conditions and fill an unmet medical need, with the purpose of getting important new drugs to patients sooner.
Pritelivir Clinical Phase 2 Study
AiCuris Initiates U.S. Clinical Phase 2 Trial with Oral Pritelivir for the Treatment of HSV Infections in Immunocompromised Adults
Opening of the first site in its clinical phase 2 study, PRIOH-1, to evaluate the efficacy and safety of oral pritelivir.
Join AiCuris and its quest for novel Anti-Infectives
We offer an exciting and challenging working enviroment in an innovative company with a world-class R&D Portfolio.